Future paradigms for precision oncology

J 2016

Future paradigms for precision oncology

KLEMENT, Giannoula Lakka, Knarik ARKUN, Dalibor VALÍK, Tina ROFFIDAL, Ali HASHEMI et. al.

Basic information

Original name

Future paradigms for precision oncology

Authors

KLEMENT, Giannoula Lakka (840 United States of America), Knarik ARKUN (840 United States of America), Dalibor VALÍK (203 Czech Republic, belonging to the institution), Tina ROFFIDAL (840 United States of America), Ali HASHEMI (124 Canada), Christos KLEMENT (124 Canada), Paolo CARMASSI (124 Canada), Edward RIETMAN (124 Canada), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Pavel MAZÁNEK (203 Czech Republic, belonging to the institution), Peter MÚDRY (203 Czech Republic, belonging to the institution), Gabor KOVACS (348 Hungary), Csongor KISS (348 Hungary), Koen NORGA (56 Belgium), Dobrin KONSTANTINOV (100 Bulgaria), Nicolas ANDRÉ (250 France), Irene SLAVC (40 Austria), Henk van DEN BERG (528 Netherlands), Alexandra KOLENOVA (703 Slovakia), Leoš KŘEN (203 Czech Republic), Jiří TŮMA (203 Czech Republic, belonging to the institution), Jarmila SKOTÁKOVÁ (203 Czech Republic, belonging to the institution) and Jaroslav ŠTĚRBA (203 Czech Republic, guarantor, belonging to the institution)

Edition

Oncotarget, Albany, Impact Journals, 2016, 1949-2553

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.168

RIV identification code

RIV/00216224:14110/16:00088934

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.18632/oncotarget.9488

UT WoS

000385402300150

Keywords in English

precision medicine; targeted therapy; genomics; metronomic chemotherapy

Abstract

V originále

Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types. This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required. While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.

Links

LM2015090, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

NV16-33209A, research and development project

Name: Sekvenování nové generace a expresní profilování jako diagnostický podklad pro návrhy individualizovaných léčebných plánů pro děti se solidními nádory

NV16-34083A, research and development project

Name: Receptorové tyrozinkinázy a navazující signální dráhy jako potenciální cíle léčby refrakterních solidních nádorů dětského věku

90089, large research infrastructures

Name: BBMRI-CZ II

Citovat

KLEMENT, Giannoula Lakka, Knarik ARKUN, Dalibor VALÍK, Tina ROFFIDAL, Ali HASHEMI, Christos KLEMENT, Paolo CARMASSI, Edward RIETMAN, Ondřej SLABÝ, Pavel MAZÁNEK, Peter MÚDRY, Gabor KOVACS, Csongor KISS, Koen NORGA, Dobrin KONSTANTINOV, Nicolas ANDRÉ, Irene SLAVC, Henk van DEN BERG, Alexandra KOLENOVA, Leoš KŘEN, Jiří TŮMA, Jarmila SKOTÁKOVÁ and Jaroslav ŠTĚRBA. Future paradigms for precision oncology. Oncotarget. Albany: Impact Journals, 2016, vol. 7, No 29, p. 46813-46831. ISSN 1949-2553. Available from: https://dx.doi.org/10.18632/oncotarget.9488.

@article{1366314,
   author = {Klement, Giannoula Lakka and Arkun, Knarik and Valík, Dalibor and Roffidal, Tina and Hashemi, Ali and Klement, Christos and Carmassi, Paolo and Rietman, Edward and Slabý, Ondřej and Mazánek, Pavel and Múdry, Peter and Kovacs, Gabor and Kiss, Csongor and Norga, Koen and Konstantinov, Dobrin and André, Nicolas and Slavc, Irene and Den Berg, Henk van and Kolenova, Alexandra and Křen, Leoš and Tůma, Jiří and Skotáková, Jarmila and Štěrba, Jaroslav},
   article_location = {Albany},
   article_number = {29},
   doi = {http://dx.doi.org/10.18632/oncotarget.9488},
   keywords = {precision medicine; targeted therapy; genomics; metronomic chemotherapy},
   language = {eng},
   issn = {1949-2553},
   journal = {Oncotarget},
   title = {Future paradigms for precision oncology},
   url = {http://dx.doi.org/10.18632/oncotarget.9488},
   volume = {7},
   year = {2016}
}

TY  - JOUR
ID  - 1366314
AU  - Klement, Giannoula Lakka - Arkun, Knarik - Valík, Dalibor - Roffidal, Tina - Hashemi, Ali - Klement, Christos - Carmassi, Paolo - Rietman, Edward - Slabý, Ondřej - Mazánek, Pavel - Múdry, Peter - Kovacs, Gabor - Kiss, Csongor - Norga, Koen - Konstantinov, Dobrin - André, Nicolas - Slavc, Irene - Den Berg, Henk van - Kolenova, Alexandra - Křen, Leoš - Tůma, Jiří - Skotáková, Jarmila - Štěrba, Jaroslav
PY  - 2016
TI  - Future paradigms for precision oncology
JF  - Oncotarget
VL  - 7
IS  - 29
SP  - 46813-46831
EP  - 46813-46831
PB  - Impact Journals
SN  - 19492553
KW  - precision medicine
KW  - targeted therapy
KW  - genomics
KW  - metronomic chemotherapy
UR  - http://dx.doi.org/10.18632/oncotarget.9488
L2  - http://dx.doi.org/10.18632/oncotarget.9488
N2  - Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types. This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required. While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.
ER  -

KLEMENT, Giannoula Lakka, Knarik ARKUN, Dalibor VALÍK, Tina ROFFIDAL, Ali HASHEMI, Christos KLEMENT, Paolo CARMASSI, Edward RIETMAN, Ondřej SLABÝ, Pavel MAZÁNEK, Peter MÚDRY, Gabor KOVACS, Csongor KISS, Koen NORGA, Dobrin KONSTANTINOV, Nicolas ANDRÉ, Irene SLAVC, Henk van DEN BERG, Alexandra KOLENOVA, Leoš KŘEN, Jiří TŮMA, Jarmila SKOTÁKOVÁ and Jaroslav ŠTĚRBA. Future paradigms for precision oncology. \textit{Oncotarget}. Albany: Impact Journals, 2016, vol.~7, No~29, p.~46813-46831. ISSN~1949-2553. Available from: https://dx.doi.org/10.18632/oncotarget.9488.

Detailed Information on Publication Record